Notch is out — your watchlist beside the MacBook notch, synced with this account.
Learn more ↗We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Auto-summary of recent filing activity and financial trends · not investment advice
Samsung BioLogics has recently filed frequent 'Other' and 'Correction' disclosures. Regular disclosures, including quarterly, business, and audit reports, have also been consistently submitted. While revenue for Q2 2026 increased compared to Q1 2026, net profit decreased. Changes in financial metrics are observed alongside these various disclosure activities.
Latest filings collected from DART (electronic disclosure system)
